Palatin Technologies

340 articles with Palatin Technologies

• Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

  5/17/2022

  Palatin Technologies, Inc. today announced results for its fiscal third quarter ended March 31, 2022.

• Palatin Announces $15 Million Private Placement of Convertible Redeemable Preferred Stock

  5/12/2022

  Palatin Technologies, Inc. announced that it has entered into a securities purchase agreement with institutional investors pursuant to which Palatin will issue and sell 8,100,000 shares of its Series B convertible redeemable preferred stock and 900,000 shares of its Series C convertible redeemable preferred stock to such investors.

• Palatin to Report Third Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on May 17, 2022

  5/11/2022

  Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2022 operating results on Tuesday, May 17, 2022 , before the open of the U.S. financial markets.

• Palatin to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference

  5/2/2022

  Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Conference being held May 1-4 in Denver.

• Palatin to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022

  4/21/2022

  Palatin Technologies, Inc. today announced that Carl Spana, Ph.D., President and CEO of Palatin, will deliver a presentation today at the Eyecelerator@ASCRS 2022 Conference in Washington D.C. 

• Palatin Hosting Key Opinion Leader Webinar on Dry Eye Disease

  3/3/2022

  Palatin Technologies, Inc. today announced that it will host a key opinion leader (KOL) webinar on the unmet medical need in treating patients with dry eye disease (DED) on Monday, March 7, 2022 at 10:30 am ET.

• Palatin Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

  2/15/2022

   Palatin Technologies, Inc. today announced results for its fiscal second quarter ended December 31, 2021.

• Palatin to Report Second Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on February 15, 2022

  2/10/2022

  Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2022 operating results on Tuesday, February 15, 2022 , before the open of the U.S. financial markets.

• Palatin Announces Presentation at the 2022 Crohn's and Colitis Congress

  1/21/2022

  Palatin Technologies, Inc. (NYSE American: PTN), announced a presentation of the positive effects of PL8177 on treating ulcerative colitis in an animal disease model, including genomic data characterizing the anti-inflammatory effects of melanocortin agonists.

• Palatin to Present at H.C. Wainwright BioConnect Conference

  1/7/2022

  Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced that the Company will present and host one-on-one meetings at the H.C. Wainwright BioConnect Virtual Conference being held January 10–13, 2022.

• 

  4 Life Sciences Companies Hit the Ground Running in 2022

  12/30/2021

  In addition to the beginnings of the Jazz PTSD study, Revive announced its Phase III study of Bucillamine in patients with mild to moderate COVID-19 will continue. 

• Palatin Announces Initiation of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial in Patients with Dry Eye Disease

  12/28/2021

  Palatin Technologies, Inc. announced the initiation of the pivotal Phase 3 MELODY-1 clinical study of PL9643 in patients with dry eye disease.

• Notice of Allowance Issued for Method of Treating Cytokine Storm Using Melanocortin-Specific Peptide

  11/30/2021

  Palatin Technologies, Inc. today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for application No.: 16/927,347.

• Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate Update

  11/15/2021

  Palatin Technologies, Inc. today announced results for its first fiscal quarter ended September 30, 2021.

• Palatin to Report First Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on November 15, 2021

  11/10/2021

  Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2022 operating results on Monday, November 15, 2021 before the open of the U.S. financial markets.

• Palatin Awarded Top 10 Poster Designation at the American Society of Retina Specialists (ASRS) 2021 Annual Meeting

  10/22/2021

  ASRS Top 10 awarded to Palatin's pre-clinical diabetic retinopathy poster demonstrating positive effects of melanocortin agonists for retinal inflammation

• Palatin Reports Fourth Quarter and Full Year Fiscal Year 2021 Financial Results and Provides Corporate Update

  9/29/2021

  - Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Currently Expected to Start Next Quarter with Top-Line Results Expected in the Second Half Calendar 2022

• Palatin Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting

  9/27/2021

  Palatin Technologies, Inc. announced the presentation of the protective effects of melanocortin 1 receptor agonists PL8331 and PL9654 in mouse models of retinopathy, at the 2021 Annual Meeting of the American Society of Retina Specialists (ASRS), being held virtually October 8-12, 2021.

• Palatin To Report Fourth Quarter And Fiscal Year End 2021 Results; Teleconference And Webcast To Be Held On September 29, 2021

  9/24/2021

  Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2021 operating results on Wednesday, September 29, 2021

• Palatin to Present Peptides Platform at the TIDES USA Conference

  9/15/2021

  Palatin Technologies, Inc. today announced a featured speaker presentation and two poster presentations at the upcoming TIDES USA hybrid conference in Boston, Massachusetts on September 20-23, 2021.